Breast scintigraphy: Procedure guidelines for tumour imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 12, 2003, Pages

  Bombardieri, Emilio ^a   Aktolun, Cumali ^b   Baum, Richard P ^c   Bishof Delaloye, Angelika ^d   Buscombe, John ^e   Chatal, Jean François ^f   Maffioli, Lorenzo ^g   Moncayo, Roy ^h   Mortelmans, Luc ⁱ   Reske, Sven N ^j  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b KOCAELI UNIVERSITY   (Turkey)

^c PET Center   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g A MANZONI HOSPITAL   (Italy)

^h UNIVERSITY OF INNSBRUCK   (Austria)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF ULM   (Germany)

more..

Author keywords

Breast scintigraphy; Indications; Procedure guidelines; Scintimammography Tumour imaging

Indexed keywords

BREAST CARCINOMA; BREAST TUMOR; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; IMAGE PROCESSING; PRACTICE GUIDELINE; RADIATION DOSE; REVIEW; SCINTIMAMMOGRAPHY; TECHNIQUE;

EID: 0347364786     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1354-3     Document Type: Review

References (60)

1. Allen MW, Hendi P, Bassett L, Phelps ME, Gambhir SS. A study on the cost effectiveness of sestamibi scintimammography for screening women with dense breasts for breast cancer. Breast Cancer Res Treat 1999; 55:243-258.
2. Allen MW, Hendi P, Schwimmer J, Bassett L, Gambhir SS. Decision analysis for the cost effectiveness of sestamibi scintimammography in minimizing unnecessary biopsies. Q J Nucl Med 2000; 44:168-185.
3. Alonso O, Delgado L, Nunez M, et al Predictive value of 99mTc-sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer. Nucl Med Commun 2002; 23:765-771.
4. 99mTc-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. Nucl Med Commun 1999; 20:317-325.
5. Bombardieri E, Crippa F. PET imaging in breast cancer. Q J Nucl Med 2001; 45:245-256.
6. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, Dankerl A, Glatting G, Reske S, Mattfeldt T. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 29:1317-1323.
7. Buscombe JR, Cwikla JB, Holloway B, Hilson AJ. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. J Nucl Med 2001; 42:3-8.
8. Cwikla JB, Buscombe JR, Kolasinska AD, Parbhoo SP, Thakrar DS, Hilson AJ. Correlation between uptake of Tc-99m sestaMIBI and prognostic factors of breast cancer. Anticancer Res 1999; 19:2299-2304.
9. Cwikla JB, Kolasinska A, Buscombe JR, Hilson AJ. Tc-99m MIBI in suspected recurrent breast cancer. Cancer Biother Radiopharm 2000; 15:367-372.
10. 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75:135-146.
11. 99mTc-sestamibi as a complementary diagnostic technique in the detection of breast cancer. Acta Radiol 2000; 41:441-445.
12. Del Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of p-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997; 38:1348-1351.
13. Derebek E, Balci P, Alanyali H, et al. Detection of bilateral multifocal breast cancer using Tc-99m sestamibi imaging. The role of delayed imaging. Clin Nucl Med 1999; 24:590-593.
14. Diggles L, Mena I, Khalkhali I. Technical aspects of prone dependent-breast scintimammography. J Nucl Med Tech 1994; 22:165-170.
15. 99mTc-MIBI scintimammography. Ann Nucl Med 1998; 12:307-312.
16. Fuster D, Vinolas N, Mallafre C, Pavia J, Martin F, Pons F. Tetrofosmin as predictor of tumour response. Q J Nucl Med 2003; 47:58-62.
17. Greco C, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93:630-635.
18. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino] ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34:30-38.
19. Horne T, Pappo I, Cohenpour M, Mindlin L, Orda R. 99Tc-MIBI scintimammography for the detection of breast malignancies: the contribution of the count ratio to specificity. Nucl Med Commun 1999; 20:511-516.
20. Horne T, Pappo I, Cohen-Pour M, Baumer M, Orda R. 99Tc(m)-tetrofosmin scintimammography for detecting breast cancer: a comparative study with 99Tc(m)-MIBI. Nucl Med Commun 2001; 22:807-811.
21. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1998; 28:3.
22. 99mTc-MIBI versus dynamic MRI for non-invasive characterization of breast masses. Eur J Nucl Med 2001; 28:56-63.
23. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med 1999; 29:221-236.
24. Kao CH, Tsai SC, Liu TJ, Ho YJ, Wang JJ, Ho ST, ChangLai SP. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res 2001; 61:1412-1414.
25. Khalkhali I, Itti E. Functional breast imaging using the single photon technique Nucl Med Commun 2002; 23:609-611.
26. Khalkhali I, Diggles LE, Taillefer R, Vandestreek PR, Peller PJ, Abdel-Nabi HH. Procedure guideline for breast scintigraphy. Society of Nuclear Medicine. J Nucl Med 1999; 40:1233-1235.
27. 99mTc-sestamibi breast imaging: multicenter trial results. J Nucl Med 2000; 41:1973-1979.
28. 99mTc-sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study. Radiology 2002; 222:149-155.
29. Leidenius MH, Leppanen EA, Tykka HT et al The role of Tc99m-sestamibi scintigraphy in combination with the triple assessment of primary breast cancer. Eur J Surg Oncol 2002; 28:108-112.
30. Leung JW. New modalities in breast imaging: digital mammography, positron emission tomography, and sestamibi scintimammography. Radiol Clin North Am 2002; 40:467-482.
31. Lumachi F, Ferretti G, Povolato M, et al. Usefulness of 99mTc-sestamibi scintimammography in suspected breast cancer and in axillary lymph node metastases detection. Eur J Surg Oncol 2001; 27:256-259.
32. Maffioli L, Agresti R, Chiti A, et al. Prone scintimammography in patients with non-palpable breast lesions. Anticancer Res 1996; 16:1269-1274.
33. Maffioli L, Steens J, Pauwels EJ, Bombardieri E. Application of Tc-99m sestamibi in oncology. Tumori 1996; 82:12-21.
34. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999; 85:2410-2423.
35. Marian T, Szabo G, Goda K, et al. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging 2003; 30:1147-1154.
36. Mlikotic A, Mishkin FS. Visualization of the right atrial appendage during sestamibi scintigraphy. Clin Nucl Med 2000; 25:848-849.
37. Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med 1997; 38:428-432.
38. Obwegeser R, Berghammer P, Rodrigues M, et al. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999; 26:1553-1559.
39. Palmedo H, Schomburg A, Grunwald F, et al. Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer. Nucl Med Biol 1996; 23:681-684.
40. Palmedo H, Biersack HJ, La Storia S, Maublant J, Prats E, Stegner HE, Bourgeois P, Hustinx R, Hilson AJW, Bischof Delaloye A. Scintimamography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentric trial. Eur J Nucl Med 1998; 25:375-385.
41. Palmedo H, Hensel J, Reinhardt M, von Mallek D, Matthies A, Biersack HJ. Breast cancer imaging with PET and SPECT agents: an in vivo comparison. Nucl Med Biol 2002; 29:809-815.
42. m-sestamibi scintimammography in the diagnosis of breast cancer. Nucl Med Commun 2000; 21:341-348.
43. Peller P, Khedkar N, Martinez C. Breast tumor scintigraphy. J Nucl Med Tech 1996; 24:198-203.
44. Rem RF, Schoonjans JM, Kieper DA et al. High-resolution scintimammography: a pilot study. J Nucl Med 2002; 43:909-915.
45. 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines. J Nucl Med 2000; 41:1495-1499.
46. Schillaci O, Scopinaro F, Spanu A, Donnetti M, Danieli R, Di Luzio E, Madeddu G, David V. Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintigraphy. Int J Oncol 2002; 20:483-487.
47. 99mTc-tetrofosmin SPET in the detection of both primary breast cancer and axillary lymph node metastasis. Eur J Nucl Med 2001; 28:1781-1794.
48. 99mTc-tetrofosmin SPECT scintimammography in the detection of small size primary breast carcinomas. Int J Oncol 2002; 21:831-840.
49. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Kao CH. Expression of drug resistance protein related to Tc-99m MIBI breast imaging. Anticancer Res 2000; 20:2021-2025.
50. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett 2000; 153:95-100.
51. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. Semin Nucl Med 1999; 29:16-40.
52. Taillefer R, Robidoux A, Lambert R, et al. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36:1758-1765.
53. Tiling R, Sommer H, Pechmann M, et al. Comparison of technetium-99m sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38:58-62.
54. Tiling R, Tatsch K, Sommer H, et al. Technetium-99m sestamibi scintimammography for the detection of breast carcinoma: comparison between planar and SPECT imaging. J Nucl Med 1998; 39:849-856.
55. Tornai MP, Bowsher JE, Jaszczak RJ, Pieper BC, Greer KL, Hardenbergh PH, Coleman RE. Mammotomography with pinhole incomplete circular orbit SPECT. J Nucl Med 2003; 44:583-593.
56. Vargas HI, Agbunag RV, Kalinowski A, et al The clinical utility of Tc-99m sestamibi scintimammography in detecting multicentric breast cancer. Am Surg 2001; 67:1204-1208.
57. Villanueva-Meyer J, Leonard MH, Briscoe E, et al. Mammoscintigraphy with technetium-99m sestamibi in suspected breast cancer. J Nucl Med 1996; 37:926-930.
58. Wang HC, Sun SS, Kao A, et al. Comparison of technetium-99m methoxyisobutylisonitrile scintimammography ultrasonography in the diagnosis of breast cancer patients with mammographically dense breast. Cancer Invest 2002; 20:318-323.
59. Wu D, Gambhir SS. Positron emission tomography in diagnosis and management invasive breast cancer: current status and future perspectives. Clin Breast Cancer 2003; 4:S55-S63.
60. Yang MD, Sun SS, Kao CH, Lin CC, Lee CC. Usefulness of technetium-99m tetrofosmin scintimammography to detect breast cancer in mammographically dense breasts. Cancer Invest 2002; 20:518-523.